Micrima papers accepted for the Cambridge conference on breast cancer imaging
Micrima is pleased to announce they have just had 2 papers on our Radio-wave imaging technology MARIA™ accepted for the upcoming Cambridge conference on breast cancer imaging. These papers are;
The first presentation of final statistics from the completed study of this whole-breast, non-compressing modality which does not employ ionizing radiation.
From a total of 223 evaluable cases, 80 were confirmed as cancer by means of histology post-image guided biopsy. For these studies, MARIA™’s overall sensitivity was calculated as 75%; in pre-/peri-menopausal women, sensitivity was 71%; in post-menopausal, it was 77%; in women with dense breasts (BI-RADS c and d) it was 86%
The second paper discusses a commercial radio-wave breast imaging system (MARIA™, Micrima Limited, Bristol) modified to support triggered data capture in systolic and diastolic states as part of a multi-site symptomatic clinical trial
Come and see us at the Cambridge conference on breast imaging to find out more or check out the clinical information section of the website